Merck Wilmington Biotech will serve as a launch and commercial production facility and the future U.S. home for KEYTRUDA. RAHWAY, N.J., April 29, 2025--(BUSINESS WIRE)--Merck (NYS ...

New Jersey-based pharmaceutical giant Merck is investing $1 billion in what company executives described as a continued ...

Last year, Keytruda generated ... approved a $30.2 million grant to Merck, contingent on the company’s decision to set up operations at the Chestnut Run Innovation & Science Park (CRISP ...

IO Biotech was named to Fast Company’s World’s Most Innovative Companies of 2025 list for its potentially game-changing approach to immune-modulatory cancer vaccines, earning its place on the coveted ...

Located at Chestnut Run Innovation & Science Park, the Merck Wilmington Biotech project will comprise laboratory, ...

Merck & Co.‘s planned debut this fall of an injectable form of its breakthrough cancer treatment Keytruda will simplify care, ...

In this week’s edition of InnovationRx, we look at a patent fight over the world’s top-selling drug, breakthroughs from the American Association for Cancer Research, Verily’s Parkinson’s dataset, the ...

Merck announced on Tuesday that it is investing $1 billion in a new Delaware plant to expand domestic production as it ...

A groundbreaking ceremony was held at Chestnut Run Innovation & Science Park on April 29, bringing together business and ...

Merck has initiated construction of a $1 billion, 470,000-square-foot biologics center of excellence in Wilmington, Delaware.

IF THERE’S one thing every American agrees on, it’s that politics has become vicious. There are plenty of explanations for ...

Merck starts construction on a $1B biologics facility in Wilmington, Del., expected to create 500+ jobs and support Keytruda production.